The US FDA has given approval for Israel’s Redhill Biopharma to market its RHB-105 (Talicia) treatment for the treatment of Helicobacter pylori (H. pylori). It follows successful Phase 3 trials, as reported (here) previously. H. pylori affects some 2 million … Continue reading →

Israeli biotech Redhill announced positive top-line results from its confirmatory Phase 3 study using its TALICIA treatment for H. pylori Infection. Of 455 trial participants, the antibiotic-resistant infection was eradicated completely in 85% of cases compared to 58% using an … Continue reading →

Israeli biotech Redhill announced positive results of the Phase 3 trial for RB-104 in treating Crohn’s disease which affects 1.5 million people worldwide. https://www.timesofisrael.com/redhills-drug-for-crohns-disease-shows-positive-results-study/

Israeli biotech Redhill has announced that the Phase 3 trial of its BEKINDA treatment for acute gastroenteritis and gastritis, on 321 patients in 21 US clinical sites, met its targets for efficacy and safety. There are some 179 million cases … Continue reading →

Israelis Dror Ben-Asher and Ori Shilo founded the biotech RedHill BioPharma – named after the earth-red hill that the kibbutz overlooked. Now their company is successfully trialing treatments to cure Crohn’s disease, Helicobacter pylori, stomach cancer and much more. http://www.timesofisrael.com/kibbutz-duo-turned-entrepreneurs-on-quest-to-whip-gut-bugs/

Israel’s Redhill Biopharma announced positive top-line results from its Phase III study with RHB-105 for treating Helicobacter pylori (H. pylori) infections. RHB-105 achieved 89.4% efficacy in eradicating H. pylori with no serious adverse events or unexpected safety issues. http://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1358&PID=0&IID=1947

Normally, foreign investors acquire Israeli biotechs that develop cancer treatments. But here, Israel’s Redhill Biopharma has bought pancreatic cancer treatment RP101 from Germany’s RESprotect GmbH. RP101 has passed Phase II trials and has vital orphan status. http://ir.redhillbio.com/releasedetail.cfm?ReleaseID=866033

Israel’s Redhill Biopharma announced preliminary positive data from a pre-clinical study with RHB-104 for the treatment of Type 1 diabetes. Trials of RHB-104 for treating Crohn’s disease and Multiple Sclerosis are on going and are planned for Rheumatoid Arthritis. http://online.wsj.com/article/PR-CO-20140626-905884.html

Israel’s Redhill Biopharma announced success in Phase III trials of RHB-102 – a once-a-day pill for the prevention of nausea in cancer patients. Redhill now plans to apply to the US Food and Drug Administration for a pre-New Drug Application … Continue reading →